Welcome to our dedicated page for Know Labs news (Ticker: $KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Know Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Know Labs's position in the market.
Know Labs, Inc. (KNW) has been chosen to present an oral abstract at the 2024 American Association of Clinical Endocrinology Annual Meeting. The abstract, titled 'Efficacy of a Non-Invasive Blood Glucose Monitor for Diabetes Management Using a Radiofrequency Sensor and Machine Learning,' will showcase the accuracy and medical application of its proprietary sensor. The company will continue deploying its KnowU™ wearable continuous glucose monitor in large-scale clinical trials toward FDA clearance, focusing on performance in real-world environments and extreme glycemic ranges.
Know Labs, Inc. (NYSE American: KNW) will host a webcast on May 15, 2024, to review Q2 FY 2024 results. The company is focused on non-invasive medical diagnostic technology, including a continuous blood glucose monitoring device.